StockNews.com assumed coverage on shares of Cellectis (NASDAQ:CLLS - Free Report) in a research report released on Wednesday morning. The brokerage issued a buy rating on the biotechnology company's stock.
Separately, Barclays cut their target price on shares of Cellectis from $7.00 to $5.00 and set an "overweight" rating for the company in a research note on Tuesday, November 5th.
Check Out Our Latest Report on Cellectis
Cellectis Price Performance
NASDAQ CLLS traded down $0.01 during trading on Wednesday, reaching $1.53. 76,715 shares of the company traded hands, compared to its average volume of 179,377. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.78 and a current ratio of 1.78. The stock's 50 day moving average price is $1.63 and its two-hundred day moving average price is $1.91. The company has a market cap of $85.04 million, a price-to-earnings ratio of -1.18 and a beta of 3.06. Cellectis has a 1-year low of $1.41 and a 1-year high of $3.38.
Institutional Investors Weigh In On Cellectis
Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Wells Fargo & Company MN raised its holdings in shares of Cellectis by 103.4% in the 4th quarter. Wells Fargo & Company MN now owns 24,590 shares of the biotechnology company's stock valued at $44,000 after purchasing an additional 12,500 shares during the period. Millennium Management LLC bought a new position in Cellectis in the 4th quarter valued at about $962,000. Finally, B Group Inc. bought a new position in Cellectis in the 4th quarter valued at about $5,547,000. 63.90% of the stock is owned by institutional investors.
Cellectis Company Profile
(
Get Free Report)
Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.
See Also
Before you consider Cellectis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cellectis wasn't on the list.
While Cellectis currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
